News
HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...
19h
TheHealthSite on MSNWhat Is Lenacapavir? All About WHO Recommended Biannual HIV Prevention DrugA breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...
The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...
10h
GlobalData on MSNViiV’s HIV shot preferred, as activists spotlight funding crisis at IAS 2025Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.
GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment
GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...
Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...
The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...
13h
AllAfrica on MSNRwanda in Talks to Get New HIV Injectable DrugA newly approved HIV prevention drug, lenacapavir, is set to be introduced in at least nine countries in early 2026, and ...
In a major advancement in the global fight against HIV, the World Health Organization (WHO) has recommended the use of ...
14h
GlobalData on MSNMSD progresses once-monthly HIV PrEP into Phase IIIMSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.
Global deaths from AIDS have dropped to their lowest levels in more than 30 years, but US funding cuts could soon reverse that progress.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results